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Abstract 
The difference in intraluminal intensity of blood speckle (IBS) on integrated 
backscatter-intravascular ultrasound (IB-IVUS) across a coronary artery stenosis (i.e. ΔIBS) has 
previously shown a negative correlation with fractional flow reserve, reflecting impaired 
coronary blood flow. Periprocedural myocardial injury (PMI) after coronary stenting has also 
been associated with coronary circulatory dysfunction. The aim of this study was to investigate 
the relation between ΔIBS after coronary stenting and PMI. A total of 180 patients undergoing 
elective coronary stenting under IVUS-guidance for a single lesion were included. Intraluminal 
IBS was measured using IB-IVUS in cross-sections at the ostium of the target vessel and at the 
distal reference of the stent. ΔIBS was calculated as (distal IBS value) – (ostium IBS value). PMI 
was defined as elevation of troponin I >5 times the 99th percentile upper reference limit (>0.45 
ng/ml) within 24 hours post procedure. Mean ΔIBS after coronary stenting was 6.52±5.71. There 
were significantly greater use of rotational atherectomy, number of stents, total stent length, and 
ΔIBS in patients with PMI than those without. In the receiver operating characteristic curve 
analysis, ΔIBS significantly predicted PMI (AUC 0.64, best cut-off value 7.88, p=0.001). 
Multiple logistic regression analysis determined that total stent length, use of rotational 
atherectomy, and ΔIBS were independent predictors of PMI. In conclusion, greater ΔIBS assessed 
by IB-IVUS was significantly associated with PMI after coronary stenting in patients with stable 
coronary artery disease. 
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Percutaneous coronary intervention (PCI) has become the predominant procedure for 
coronary revascularization among patients with coronary artery disease.
1
 However, it has 
previously been reported that 10% to 40% of elective PCI procedures are accompanied by 
periprocedural myocardial injury (PMI),
2
 which is associated with increased long-term adverse 
cardiac events.
3-6
 Although PMI has been mostly caused by side-branch occlusion, it may also be 
induced by micro-embolization and impaired coronary blood flow after PCI.
7,8
 Recently, the 
difference in intraluminal intensity of blood speckle (IBS) on integrated backscatter-intravascular 
ultrasound (IB-IVUS) across a coronary artery stenosis (i.e. ΔIBS) has shown a correlation with 
fractional flow reserve value,
9,10
 suggesting that ΔIBS is considered an index reflecting coronary 
blood flow. The aim of this study was to investigate the relation between ΔIBS and PMI after 
coronary stent implantation. 
 
Methods 
From January 2015 to July 2017, a total of 550 patients with coronary artery disease 
undergoing PCI at Chiba University Hospital were screened for eligibility. Patients were 
considered eligible for this study when IVUS-guided coronary stenting demonstrated final 
Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow in the target vessel without any 
occlusion of side branches. Major criteria for exclusion were patients with acute coronary 
syndrome, lack of values of pre- or post-procedural troponin I (TnI), PCI for more than 2 vessels 
on the same day, hemodialysis, and inadequate IVUS images. Thus, 180 patients were included in 
the present study (Figure 1). TnI values were obtained before and 12 to 24 hours after PCI by 
enzyme immunoassay method (Tosoh, Tokyo, Japan). PMI was defined as post-procedural 
elevation of TnI >5 times the 99th percentile upper reference limit (i.e. >0.45 ng/ml), according 
to the Third Universal Definition of Myocardial Infarction.
11
 Written informed consent for 
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examination was obtained from all patients, and the Ethical Committee of Chiba University 
approved this study.  
Coronary angiography was analyzed quantitatively by QAngio XA (Version 7.1, Medis 
Medical Imaging System BV, Leiden, the Netherlands). Reference vessel diameter, minimum 
lumen diameter, percentage diameter stenosis, and lesion length were measured by a program 
automatically.
12
 
All IVUS examinations were performed after intracoronary administration of isosorbide 
dinitrate 1 to 2 mg. IVUS imaging data were acquired with a commercially available IVUS 
imaging system (VISIWAVE, Terumo, Tokyo, Japan) using a 43-MHz mechanically rotating 
IVUS catheter (ViewIT, Terumo) with a motorized transducer pullback speed of 0.5 mm/s after 
the last balloon inflation. Pullback of IVUS catheter was started from the distal reference site of 
the implanted stent to the ostium of the target vessel. All IVUS measurements were performed by 
2 experienced cardiologists, who were unaware of the patients’ clinical characteristics, according 
to the American College of Cardiology Clinical Expert Consensus Document on Standards for 
Acquisition, Measurement, and Reporting of Intravascular Ultrasound Studies.
13
 Offline IVUS 
analysis was performed using a computerized system (VISIATLAS, Terumo). In cross-sectional 
analysis, stent, lumen, and external elastic membrane areas were manually traced to assess stent, 
lumen, vessel, and plaque areas. After successful stenting, intraluminal IBS was measured at the 
ostium of the target vessel (ostium IBS) and at the distal reference of the stent within 5 mm 
(distal IBS) (Figure 2A). By manually tracing the borders of the lumen and IVUS catheter, and 
excluding the guidewire and acoustic shadow, intraluminal IBS was calculated as (IB value of 
lumen area) – (IB value of IVUS catheter area) – (IB value of the guidewire and acoustic 
shadow) in the diastolic frames (Figure 2B). Cross-sections with major side branches were 
avoided, and adjacent slices were adequately selected for this analysis. ΔIBS was defined as 
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(distal IBS) – (ostium IBS). 
Data are expressed as the mean ± standard deviation or median (interquartile range) as 
appropriate. Continuous variables with normal distribution were compared using Student’s t-test 
and categorical variables were compared by Fisher’s exact test. Continuous variables that did not 
follow a normal distribution were compared using Mann-Whitney test. The receiver operating 
characteristic curve analysis was performed to determine the optimal cut-off value of ΔIBS to 
predict PMI. The associated variables in univariate models (p<0.10) were included in the 
multivariate model using the stepwise forward selection method to identify the independent 
predictors of PMI, presented as odds ratio with 95% confidence intervals. To evaluate reliability 
of the measurement, ΔIBS values were independently measured by 2 experienced cardiologists in 
randomly selected 20 patients. The correlation coefficient for ΔIBS was 0.90. A value of p <0.05 
was considered significant. All analyses were performed using the JMP Pro statistical software 
package (SAS Institute, Cary, NC). 
 
Results 
Table 1 lists baseline characteristics. Among 180 patients, 73 (41%) had PMI. Lesion 
characteristics are shown in Table 2. Patients with PMI underwent rotational atherectomy more 
frequently, had longer stent length and more type B2/C lesions, and tended to have more chronic 
total occlusion lesions, compared to those without PMI. In quantitative coronary angiography and 
IVUS analyses, patients with PMI had significantly smaller vessel area, minimum stent diameter 
and area, compared to those without PMI. ΔIBS was significantly greater in the patients with PMI 
compared to those without. There was a modest correlation between ΔIBS and post procedural 
TnI value (r=0.20, p=0.006). In the receiver operating characteristic curve analysis, ΔIBS 
significantly predicted PMI (AUC 0.64, best cut-off value 7.88, p=0.002). Patients with ΔIBS 
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≥7.88 had a significantly greater rate of PMI compared to those with ΔIBS <7.88 (55% vs. 32%, 
p=0.002). Multiple logistic regression analysis showed use of rotational atherectomy, total stent 
length, and ΔIBS as independent predictors of PMI (Table 3). 
 
Discussion 
The present study showed that ΔIBS was significantly associated with PMI after 
coronary stent implantation in patients without angiographically detectable impaired coronary 
blood flow in the target vessel. To the best of our knowledge, this is the first report investigating 
the relation between PMI and ΔIBS measured by IB-IVUS. In addition to ΔIBS, use of rotational 
atherectomy and total stent length were also demonstrated as independent predictors of PMI.  
Relationship between IBS and coronary blood flow was discussed in our recent study.
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In brief, IBS is mainly attributed to red blood cells,
13
 and there are reportedly various factors 
affecting IBS, such as hematocrit, erythrocyte membrane conditions, plasma fibrinogen 
disturbance, blood pH, oxygen tension, blood flow velocity, shear rate, turbulent flow, caliber of 
the vessel, pulse rate, and ultrasound frequency. Increased IBS distal to the coronary artery 
stenosis can be mainly explained by red blood cell stagnation.
13
 It is inversely related to shear 
rate, which depends on blood flow velocity when the vessel diameter does not change. Shear rate 
reduction with decrease of flow velocity can cause an increase of IBS. Therefore, increased ΔIBS 
is considered to reflect decreased coronary blood flow across the coronary stenosis, and the 
negative correlation of ΔIBS with fractional flow reserve value has recently been reported.9,10 
PMI and elevated troponin values after PCI are known to be associated with increased 
long-term mortality and recurrent myocardial infarction.
3-6
 Several predictors of PMI have been 
reported, such as older age,
14
 diffuse coronary disease,
15
 longer stent length,
6
 and use of 
rotational atherectomy.
16
 In the present study, total stent length and use of rotational atherectomy 
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were demonstrated as independent predictors of PMI in addition to ΔIBS, consistent with the 
previous studies. The incidence of PMI was 41% in this study, which was higher than previously 
reported.
6
 The relatively higher rates of complex (type B2/C) lesions, longer stent length, and 
more frequent use of rotational atherectomy, compared to those of previous reports,
6,17,18
 might 
result in the higher incidence of PMI in the present study. Although it was reported that PMI is 
mostly caused by side-branch occlusion,
7
 micro-embolization and impaired coronary blood flow 
also induce PMI.
2,8
 Patients with TIMI 2 flow have shown the association with an increased 
coronary microvascular resistance compared to those with TIMI 3 flow.
19-21
 Micro-embolization 
and subsequent inflammation by atheromatous debris during PCI may impair microvascular 
perfusion and increase resistance, leading to the reduced coronary blood flow and PMI.
2,8,22-24
 
Thus, patients with greater ΔIBS had more PMI in the present study, possibly reflecting reduced 
coronary blood flow. Although visible complications such as side branch occlusion, optical slow 
flow or no-reflow, and distal embolization were reported in approximately 20% to 75% of the 
cases with PMI,
5,7
 the others were not detectable by angiography. Therefore, ΔIBS may be useful 
to detect reduced coronary blood flow, which leads to PMI during IVUS-guided PCI. Further 
therapeutic approaches, such as adenosine or nicorandil administration, might improve coronary 
microvascular resistance and blood flow, and potentially alleviate PMI.
25,26
 Moreover, those 
patients may need more aggressive secondary preventive therapies (e.g. higher potency statin 
therapy) in order to improve long term outcomes.
27
 
There were some limitations in the present study. First, this was a retrospective 
single-center analysis, and included patients were relatively small due to a large number of 
exclusions (Figure 1). Second, we sought to adjust for potential confounders by multivariate 
analysis, however, we cannot exclude the possibility that unmeasured variables may have 
affected results, such as preprocedural C-reactive protein elevation
26
 and balloon inflation time.
46
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Third, there might be some patients with transient reduction of coronary blood flow in the 
process of PCI and consequent PMI, even though final TIMI 3 flow was achieved. Fourth, the 
patients who had a history of myocardial infarction in the target vessel were included in this 
study (n=19, 11%). In these patients, the increase of TnI might be reduced.  
In conclusion, greater ΔIBS assessed by IB-IVUS was significantly associated with PMI 
after coronary stenting in patients with stable coronary artery disease, potentially enabling the 
identification of high-risk patients requiring careful follow-up.   
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Table 1. Baseline Patient Characteristics 
Variable 
All Periprocedural Myocardial Injury 
P value 
(n=180) 
YES  
(n=73) 
NO  
(n=107) 
Men 146 (81%) 59 (81%) 87 (81%) >0.99 
Age (years) 68.5±9.3 69.0±9.6 68.2±9.0 0.53 
Medications 
 
    Dual antiplatlet therapy 171 (95%) 69 (95%) 102 (95%) >0.99 
  Anticoagulant 24 (13%) 10 (14%) 14 (13%) >0.99 
  β blocker 85 (47%) 34 (47%) 51 (48%) >0.99 
  ACE-I or ARB 100 (56%) 47 (64%) 53 (50%) 0.07 
  Statin 148 (82%) 63 (86%) 85 (79%) 0.32 
Body mass index (kg/m
2
) 23.8±3.1 23.9±2.8 23.8±3.3 0.80 
Hypertension 145 (81%) 60 (82%) 85 (79%) 0.70 
Diabetes mellitus 82 (46%) 32 (44%) 50 (47%) 0.76 
Dyslipidemia 120 (67%) 48 (66%) 72 (67%) 0.87 
Current smoker 36 (20%) 19 (26%) 17 (16%) 0.13 
Prior myocardial infarction 46 (26%) 20 (27%) 26 (24%) 0.73 
eGFR (ml/min/1.73m
2
) 67.9±18.4 70.3±16.6 66.3±19.4 0.16 
Hematocrit (%) 38.8±4.7 39.3±4.5 38.5±4.8 0.26 
Hemoglobin (g/dl) 13.0±1.7 13.2±1.7 12.9±1.7 0.18 
 Values are mean ± SD, n (%). Hypertension was defined by systolic blood pressure ≥140 mm 
Hg, diastolic blood pressure ≥90 mm Hg, or taking antihypertensive medications. Dyslipidemia 
was defined by high-density lipoprotein <40 mg/dl, low-density lipoprotein >140 mg/dl, fasting 
triglyceride >150 mg/dl, or taking lipid-lowering medications.  
ACE-I = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; eGFR 
= estimated glomerular filtration rate. 
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Table 2. Lesion Characteristics 
Variable 
All Periprocedural Myocardial Injury 
P value 
(n=180) 
YES 
(n=73) 
NO 
(n=107) 
Target coronary artery 
 
 
0.84 
   Right 60 (33%) 24 (33%) 36 (34%) 
    Left anterior descending 87 (48%) 35 (48%) 52 (49%) 
    Left circumflex 32 (18%) 14 (19%) 18 (17%) 
    Left main trunk 1 (1%) 0 (0%) 1 (1%) 
 Type B2/C lesion 117 (65%) 58 (79%) 59 (55%) <0.001 
Chronic total occlusion 15 (8%) 10 (14%) 5 (5%) 0.051 
In-stent restenosis 11 (6%) 5 (7%) 6 (6%) 0.76 
Rotational atherectomy 11 (6%) 9 (12%) 2 (2%) 0.008 
Pre dilatation 147 (82%) 63 (86%) 84 (79%) 0.24 
Post dilatation 111 (62%) 45 (62%) 66 (62%) >0.99 
Maximum inflation pressure (atm) 19.4±2.5 19.2±2.5 19.6±2.5 0.29 
Drug eluting stent 177 (98%) 72 (99%) 105 (98%) 0.80 
Number of stents 2 (1-2) 2 (1-2) 1 (1-2) <0.001 
Stent diameter (mm) 3.03±0.43 2.99±0.38 3.06±0.46 0.27 
Total stent length (mm) 45.8±25.2 55.1±23.5 39.5±24.4 <0.001 
Post procedural TnI (ng/ml) 0.27 (0.08-0.91) 1.11 (0.60-1.93) 0.11 (0.05-0.22) <0.001 
QCA analysis 
   
   Reference diameter (mm) 2.56±0.62 2.46±0.60 2.63±0.62 0.08 
   Minimum lumen diameter (mm) 0.90±0.49 0.80±0.46 0.97±0.50 0.02 
   Acute gain (mm) 1.70±0.56 1.70±0.61 1.70±0.53 0.93 
   Minimum stent diameter (mm) 2.60±0.54 2.50±0.52 2.66±0.54 0.046 
IVUS analysis 
 
 
 
   Minimum stent area (mm
2
) 5.37±2.41 4.81±2.00 5.75±2.60 0.01 
   Vessel area (mm
2
) 10.61±4.44 9.80±4.04 11.16±4.63 0.04 
   Plaque area (mm
2
) 5.25±2.53 4.99±5.47 5.42±2.57 0.27 
   ΔIBS 6.52±5.71 8.18±5.7 5.39±5.5 0.001 
Data are expressed as mean ± SD, number (percentage), or median (interquartile range).  
IBS = intraluminal intensity of blood speckle; IVUS = intravascular ultrasound; QCA = 
quantitative coronary arteriography; TnI = troponin I. 
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Table 3. Predictors of Periprocedural Myocardial Injury 
Variable Univariate   Multivariate 
  OR (95% CI) P value   OR (95% CI) P value 
ACE-I or ARB 1.84 (1.01-3.42) 0.048 
 
N/A 
 Current smoker 1.86 (0.89-3.92) 0.10 
 
N/A 
 Chronic total occlusion 3.24 (1.06-9.91) 0.04 
 
N/A 
 Rotational atherectomy 7.38 (1.83-49.43) 0.004 
 
6.48 (1.29-32.69) 0.02 
Number of stents 2.06 (1.35-3.15) <0.001 
 
N/A 
 Total stent length (mm) 1.03 (1.01-1.04) <0.001 
 
1.02 (1.01-1.04) 0.001 
Type B2/C lesion 3.15(1.62-6.39) <0.001 N/A  
Minimal stent area (mm
2
) 0.84 (0.73-0.96) 0.01  N/A  
Vessel area (mm
2
) 0.93 (0.86-1.00) 0.04  N/A  
ΔIBS 1.09 (1.03-1.16) 0.002  1.06 (1.00-1.13) 0.047 
ACE-I = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; CI = 
confidence interval; IBS = intensity of blood speckle; N/A = not applicable; OR = odds ratio. 
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Figure 1. Study Flow Chart 
ACS = acute coronary syndrome; IVUS = intravascular ultrasound; PCI = percutaneous coronary 
intervention; PMI = periprocedural myocardial injury.  
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Figure 2. Schematic Diagram of IVUS Analysis and Representative Image of IB-IVUS 
Analysis 
(A) Intraluminal IBS was measured at the ostium of the target vessel (ostium IBS) and at the 
distal reference of the stent within 5 mm (distal IBS). 
(B) IBS was calculated as (IB value of lumen area) – (IB value of IVUS catheter area) – (IB 
value of the guidewire and acoustic shadow). ΔIBS was calculated as (distal IBS) – (ostium IBS).  
IB-IVUS = integrated backscatter-intravascular ultrasound; IBS = intensity of blood speckle. 
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